Upgrade to SI Premium - Free Trial

Teva Pharma (TEVA) Attractive, Well Managed Business; Price Cut to $75 - Mizuho

May 10, 2016 6:45 AM
Mizuho analyst, Irina Koffler maintained her Buy rating after Teva Pharma (NYSE: TEVA) effectively defended its generics business and eased ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change

Next Articles